AGIO earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E -4.97. Updated 2026-07-23.
Agios Pharmaceuticals (AGIO) Research Hub
Agios Pharmaceuticals (AGIO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 33.6 USD (-2.97%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.97, market cap 2.16B. This hub links to the full technical, earnings and options research available for AGIO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 33.6 USD (-2.97%) |
| 52-week range | 29.15 USD – 44.09 USD |
| Trend regime | Range |
| 14-day RSI | 56 (Bullish) |
| Trailing P/E | -4.97 |
| Market cap | 2.16B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for AGIO
Covered Call on AGIO: how it works, illustrative setup around the real 33.6 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AGIO: how it works, illustrative setup around the real 33.6 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AGIO: how it works, illustrative setup around the real 33.6 USD price, max profit/loss, breakeven and when to use it. Educational.
AGIO technical analysis: range, last 33.6 USD, RSI 56, 52w range 29.15 USD–44.09 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is AGIO in?
Agios Pharmaceuticals (AGIO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is AGIO in an uptrend or downtrend?
As of 2026-09-11, AGIO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AGIO's trailing P/E ratio?
AGIO's trailing P/E is -4.97, with a market cap of 2.16B. See the earnings research page for full valuation detail.
When does AGIO next report earnings?
AGIO is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of -1.65877 USD.